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Subsets of NK cells can have distinct functions. Here, we report that 425% of human
peripheral blood NK cells express HLA-DR after culture with IL-2. This can be driven by an
expansion of a small subset of NK cells expressing HLA-DR, in contrast to previous
assumptions that HLA-DR is upregulated on previously negative cells. HLA-DR-expressing
NK cells showed enhanced degranulation to susceptible target cells and expressed
chemokine receptor CXCR3, which facilitated their enrichment following exposure to
CXCL11/I-TAC. Suggesting HLA-DR-expressing NK cells have an important role in an
immune response, stimulation of PBMCs with Mycobacterium bovis BCG (BCG) triggered
expansion of this subset. Importantly, the magnitude of an individual’s NK cell IFN-c
response triggered by BCG was associated with the initial frequency of HLA-DR-expressing
NK cells in PBMCs. More directly indicating the importance of HLA-DR-expressing NK
cells, enriching the frequency of this subset in PBMCs substantially augmented the IFN-c
response to BCG. Thus, HLA-DR expression marks a distinct subset of NK cells, present at
low frequency in circulating blood but readily expanded by IL-2, that can play an impor-
tant role during immune responses to BCG.
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Introduction
NK cells are lymphocytes of the innate immune system that can
directly kill transformed or virally infected target cells and are a
key source of a variety of cytokines, including IFN-g. However,
NK cells are heterogeneous in phenotype with different subsets
expressing different combinations of surface receptors [1–3]. The
best studied distinctions between NK cell subsets include CD56dim
and CD56bright populations [4, 5], and the expression of different
chemokine receptor profiles [6, 7]. Differences in the expression
profiles of chemokine receptors may suggest differential traffick-
ing of NK subsets, which likely relate to their functional roles. It
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has been established that NK cells trafficking to lymph nodes can
interact with DCs [8], for example.
Unlike the class I MHC protein, which is expressed on most
human cells, expression of class II MHC proteins is usually consid-
ered as being restricted to professional APCs. However, expression
of HLA-DR on NK cells has also been documented, where it has
sometimes been used as an activation marker because of its
increased expression following IL-2 stimulation [9–17]. HLA-DR-
expressing NK cells have been shown to present tetanus toxin and
house dust mite-derived peptides to T-cell clones in an HLA-DR-
restricted manner [18]. Antigen bound by activating NK receptors
can be internalised to class II MHC-loading compartments and
processed for subsequent HLA-DR-mediated presentation leading to
T-cell proliferation [19]. In addition, HLA-DR-expressing NK cells
have been found at elevated frequencies in inflammatory situations
such as chronically inflamed tonsil tissue and decidual NKs from
CMV-infected mothers [19]. An early study also found a correlation
between the percentage of NK cells expressing HLA-DR and the
level of NK cell-derived IFN-g transcript, suggesting a pro-inflam-
matory role for these NK cells [20]. Thus, NK cells have the ability to
present antigen, at least in certain circumstances, and here we set
out to address how HLA-DR is expressed on activated populations of
NK cells and to test the importance of the subset of NK cells that
express HLA-DR in immune responses of whole PBMCs.
We found that a distinct subset of circulating HLA-DR-
expressing NK cells in the peripheral blood preferentially prolif-
erate in response to IL-2 leading to their enrichment. This is in
contrast to the previous assumption that HLA-DR is expressed on
activated cells that were initially HLA-DR negative. We found that
HLA-DR-expressing NK cells exhibit greater lytic capacity and
express a chemokine receptor associated with both recruitment to
sites of inflammation and homing to the lymph node. In addition,
we set out to test whether or not this subset of NK cells could be
important in immune responses. We used Mycobacterium bovis
BCG (BCG) as a model pathogen, noting its common use as a
vaccine and, importantly, because of the heterogeneous NK cell
response that it elicits [21]. HLA-DR-expressing NK cells were
expanded in the response of PBMCs to BCG. Artificially enriching
the HLA-DR-expressing compartment of NK cells substantially
enhanced the response to BCG, showing that HLA-DR-expressing
NK cells can play a significant role during the initiation and
amplification of inflammatory responses.
Results
A distinct subset of human peripheral blood NK cells
expressing HLA-DR expand after IL-2 stimulation
After 6 days culture in IL-2, 25–41% (median 34%) of CD3CD561
primary NK cells, derived from peripheral blood, expressed
HLA-DR. In contrast, only 2–5.5% (median 3.5%) of fresh NK cells
ex vivo expressed HLA-DR (Fig. 1A and Supporting Information
Fig. S1A). This is consistent with previous observations [9, 22]. The
expression of HLA-DR on freshly isolated NK cells is unlikely to be a
result of incidental activation in vivo because it is not co-expressed
with the activation marker CD69 on NK cells in fresh PBMCs
(Supporting Information Fig. S2A). By comparing the expression of
HLA-DR and the activation marker CD69 on NK cells cultured for
6 days with a standard (200 U/mL) or sub-optimal (20 U/mL) dose
of recombinant (r)IL-2, we found that the proportion of HLA-DR-
expressing NK cells only increased at the higher dose, while CD69
was upregulated at both doses. Proliferation of NK cells, monitored
by CFSE dilution, was far higher with 200 U/mL IL-2 (Fig. 1B and
Supporting Information Fig. S1B and S2B) and therefore we next
set out to test whether NK cell proliferation and HLA-DR expression
were directly related.
The proportion of HLA-DR-expressing NK cells increased
gradually over 6 days of culture and was confined to cells in
which CFSE had been diluted, i.e. the proliferating cells (Fig. 1C
and 1D, Supporting Information Fig. S1C). The level of expres-
sion of HLA-DR on NK cells remained constant and it was the
proportion expressing HLA-DR that increased in proliferating
cells (Fig. 1D). Interestingly, while both IL-12 and IL-15 activate
NK cells, only IL-15 induced significant proliferation and
increased HLA-DR expression (Fig. 1E and 1G, Supporting
Information Fig. S1D and S1E). In contrast, CD69, an early
activation marker on NK cells [23], was expressed on over 95% of
the NK cells after only 48 h (Fig. 1C). Clearly, expression of
HLA-DR is not simply a marker of NK cell activation, as has been
suggested previously [9–17]. These data suggest instead that the
increase in proportion of NK cells expressing HLA-DR, in response
to IL-2 stimulation, is due to preferential expansion of a small
circulating population of HLA-DR1 cells, rather than de novo
expression on previously non-expressing cells.
Expression levels of HLA-DR are clonally restricted on
NK cells
We next tested this hypothesis using NK cell clones, i.e. where
each population of cells was expanded from a single seed cell. In
IL-2 cultured polyclonal NK cell populations, there was a broad
range of HLA-DR expression, including some HLA-DR-negative
NK cells (Fig. 1 and 2A). In contrast, HLA-DR expression was far
more homogeneous within individual NK cell clones (examples
shown in Fig. 2A). Specific comparison of the coefficients of
variance of the HLA-DR expression showed that levels of HLA-DR
expression were significantly less variable in NK cell clones than
in NK cell lines (p5 0.0004, Fig. 2A and B). Although the
absolute expression level of HLA-DR varied between clones
(Fig. 2A and C), only 6% of NK cell clones did not express
HLA-DR (Fig. 2C).
HLA-DR expression marks a subset of NK cells that
exhibit enhanced proliferation
Supporting the proliferation studies (Fig. 1), the analyses of NK
cell clones (Fig. 2A–C) suggest that HLA-DR-expressing NK cells
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proliferate more readily in response to IL-2. Thus, we explicitly
compared the proliferative potential of HLA-DR and HLA-DR1
NK cells. Freshly isolated NK cells were sorted into CD561/HLA-
DR and CD561/HLA-DR1 populations and cultured for 6 days
with IL-2. After culture, the sorted NK cell populations were
analysed by flow cytometry for expression of HLA-DR (Fig. 2D).
Figure 1. A small circulating population of NK cells expressing HLA–DR expands with IL-2. (A) Freshly isolated NK cells were analysed ex vivo (top),
and after 6 days culture with IL-2 (bottom), by flow cytometry for expression of HLA-DR on CD561 CD3 NK cells. Plots for one donor
(representative of 410 donors), showing CD561 CD3 gates (left) and HLA-DR expression on the NK cells (right), gates show percentage HLA-DR1.
(B) Freshly isolated human NK cells were labelled with CFSE and cultured for 6 days with rIL-2 at 20 U/mL (left) or 200 U/mL (right), then analysed by
flow cytometry. Plots show proliferation by CFSE (top), expression of CD69 (middle) and HLA-DR (bottom), representative of two donors. (C) Freshly
isolated human NK cells were labelled with CFSE and cultured for up to 6 days with rIL-2 (200 U/mL). NK cells were analysed by flow cytometry for
expression of HLA-DR (middle) and CD69 (right) on non-proliferating (grey shaded) and proliferating (black line) NK cells as gated in the CFSE
histogram (left). The CD69 plot for 2 days stimulation also includes the expression level ex vivo (dashed line). (D) Data for six donors comparing the
percentage of HLA-DR1 NK cells (left axis, circles and black line) and the level of expression (geomean) of HLA-DR (right axis, grey shaded area)
between each generation (distinct CFSE peaks). The percentage of HLA-DR1 NK cells is shown as a fold increase over the unproliferated cells,
median7interquartile ranges, po0.05, tested by Wilcoxon matched pairs. The level of expression was calculated as the fold increase in the
geometric mean of the HLA-DR1 NK cells relative to the total NK population. (E) Freshly isolated NK cells were labelled with CFSE and cultured with
rIL-2, rIL-12 or rIL-15 for 6 days, then analysed for expression of HLA-DR by flow cytometry. Data from a representative donor showing CFSE
profiles (left) and corresponding HLA-DR expression on CD561 NK cells (right) for stimulation by IL-12 (top) and IL-15 (bottom). (F) Data for seven
donors showing percentage of NK cells that had undergone at least one division and (G) the percentage of HLA-DR1 NK cells, po0.05, po0.01,
po0.001, tested by Wilcoxon matched pairs, median7interquartile range.
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The cultured populations derived from sorted HLA-DR1 NK cells
maintained a significant three-fold greater proportion of NK cells
expressing HLA-DR (p50.03, Fig. 2D). More importantly, there
was a marked difference in the rates of proliferation of these two
sorted populations. Immediately after sorting, the HLA-DR
population was 13-fold larger than the HLA-DR1 population.
However, after 6 days culture with IL-2 the sorted populations
were of equal size (Fig. 2E). Thus, the proliferation rate of the NK
cells in peripheral blood that express HLA-DR is significantly
greater than HLA-DR NK cells. This confirmed earlier results
that the HLA-DR-expressing NK cells preferentially proliferate in
response to IL-2 stimulation.
We used these data to calculate the percentage of HLA-DR-
expressing NK cells in a polyclonal population after 6 days culture
with IL-2 that derived from the small initial population of HLA-DR-
expressing NK cells ex vivo. This was calculated by factoring the
percentage of HLA-DR1 NK cells in each sorted population by the
relative population size, and thus calculating what contribution
each sorted population makes to the total of HLA-DR1 NK cells
after 6 days of culture with IL-2. From our experimental
observations, 54–81% (median 73%) of the HLA-DR-expressing
NK cells after 6 days culture with IL-2 derived from those that
express HLA-DR ex vivo. This is significantly higher than would be
predicted from a model with no preferential proliferation or clonal
restriction of HLA-DR expression (po0.05, Fig. 2F). Thus, HLA-DR
expression marks an NK cell phenotype that exhibits enhanced
proliferation in response to IL-2 or IL-15 stimulation. This prefer-
ential expansion of an initially small circulating population of
HLA-DR-expressing NK cells drives, in part, the increase in HLA-DR
expression following IL-2 or IL-15 stimulation. As well as being of
fundamental importance to NK cell biology this observation is
important practically because it implies that studies of cultured NK
cell clones, and IL-2 cultured NK cell lines, will be primarily
focused on the phenotype of this specific HLA-DR-expressing
subset of NK cells.
HLA-DR-expressing NK cells exhibit enhanced degran-
ulation
To test how degranulation and cytokine secretion compared
for HLA-DR positive and negative NK cells, staining for
Figure 2. Expression levels of HLA-DR on NK cells are clonally restricted. NK cell clones were analysed by flow cytometry for expression of CD56
and HLA-DR. (A) The expression of HLA-DR on a polyclonal NK cell line after 6 days IL-2 culture (left) was compared with expression on individual
clones derived from the same donor; three examples are shown (right). The coefficient of variation (CoV) of the expression of HLA-DR was
calculated for each clone and cell line (indicated in top right of histograms). (B) Coefficient of variation data for expression of HLA-DR and CD56
from 143 clones from four independent donors, po0.05, po0.0005, tested by Mann Whitney, median7interquartile range. (C) The expression
level (geomean) of HLA-DR was analysed on 129 clones from four donors. (D) Freshly isolated human NK cells were sorted into CD561/HLA-DR
(DR) and CD561/HLA-DR1 (DR1) populations. The sorted populations were cultured for 6 days with IL-2, then analysed by flow cytometry for
expression of HLA-DR and CD56. Numbers beneath gates indicate interquartile ranges (IQR) of proportions of HLA-DR-expressing NK cells from six
donors. (E) The relative population sizes of the sorted NK cell populations (/1) were compared during sorting (0 days) and after 6 days culture
with IL-2 (6d IL-2). Graphs show median7interquartile range. (F) The proportion of HLA-DR-expressing NK cells after 6 days culture with IL-2 that
derived from those that initially expressed HLA-DR ex vivo was calculated. This was compared to a null hypothesis (H0) in which no preferential
proliferation and no clonal restriction of HLA-DR expression was assumed. n5 6, po0.05 tested by Wilcoxon matched pairs.
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LAMP-1/CD107a and intracellular IFN-g production was assessed
for NK cells co-incubated with the target cell, K562 [24]. While
only 45% of HLA-DR NK cells degranulated, over 75% of
HLA-DR1 NK cells responded (p50.03, Fig. 3A and B and
Supporting Information Fig. S4A). HLA-DR-expressing NK cells
had a slightly increased capacity for IFN-g secretion upon
stimulation by K562, 22% compared with 13% for HLA-DR
NK cells, but this was not statistically significant (p5 0.09,
Fig. 3C and Supporting Information Fig. S4B). No such
distinction was seen when the cells were activated with PMA/
ionomycin (Fig. 3C), demonstrating that HLA-DR1 and HLA-DR
NK cells have the same intrinsic capacity for IFN-g production.
HLA-DR-expressing NK cells are enriched by chemo-
taxis via the chemokine receptor CXCR3
The chemokine receptor CXCR3 has previously been shown to be
expressed on a subset of NK cells [6–7], on some T cells [7] and
on conventional APCs [25, 26], and facilitates their migration to
secondary lymphoid organs [8, 27]. This chemokine receptor is
also important for lymphocyte recruitment to sites of inflamma-
tion [28]. Here, co-staining NK cells for HLA-DR and CXCR3
demonstrated that the majority of NK cells that express HLA-DR
following culture with IL-2 also express CXCR3, although this
association was not observed on the HLA-DR-expressing NK cells
ex vivo and so may reflect de novo expression (Fig. 4A and B).
Expression of CXCR3 was higher on IL-2-activated NK cells in
which CFSE was diluted (Fig. 4C), i.e. on proliferating cells, as
seen for HLA-DR (Fig. 1C). Importantly, HLA-DR-expressing NK
cells migrated in a dose-dependent manner to CXCL11/I-TAC, a
cognate chemokine for CXCR3 (Fig. 4D). This transmigration led
to a modest enrichment of the HLA-DR-expressing subset in cells
responding optimally to CXCL11/I-TAC (Fig. 4E). This enrich-
ment corresponded to the peak transmigration (Fig. 4D and E).
Furthermore, activation of CXCR3 on NK cells could be detected
via internalisation of the receptor upon recognition of CXCL11/
I-TAC, in a dose-dependent manner (Fig. 4F). These data are
consistent with HLA-DR-expressing NK cells being recruited to
sites of inflammation [10], and being able to migrate to lymph
nodes via CXCR3, which could explain the unexpectedly high
proportion of HLA-DR-expressing NK cells found in human lymph
nodes [22].
HLA-DR-expressing NK cells expand in response to
BCG stimulation
To explore the importance of these findings in the context of an
infectious agent, we investigated the response of NK cells to BCG.
BCG stimulation of whole human PBMCs for up to 6 days resulted
in a three-fold increase in the proportion of NK cells expressing
HLA-DR. Consistent with results obtained for IL-2 stimulation of
isolated NK cells, this expansion was only significant after 6 days
(po0.01, Fig. 5A). Interestingly, previous studies have demon-
strated that CD56bright NK cells constitute the majority of
proliferating lymphocytes after 6 days stimulation of PBMCs with
extracellular BCG [29, 30]. Following stimulation of PBMCs with
BCG, the NK cells produce IFN-g, similar to findings reported
previously for PBMCs stimulated with Plasmodium falciparum
infected erythrocytes [31] or with Leishmania major [32].
Interestingly, the proportion of NK cells producing IFN-g varies
considerably between donors (Fig. 5B and Supporting Informa-
tion Fig. S5). From 78 donors analysed, the median proportion of
IFN-g1 NK cells was 6.5%. Strikingly, secretion of IFN-g by NK
cells could be blocked by a neutralising mAb against IL-2
(Fig. 5C). Moreover, depleting CD31 or CD41 cells abrogated
the response. Thus, T cells, shown to produce IL-2, were
specifically required (Supporting Information Fig. S6). Interest-
ingly, as shown previously for P. falciparum stimulation, the NK
cell response was also significantly reduced by blocking class II but
not class I MHC proteins (Fig. 5C), supporting the emerging
Figure 3. HLA-DR1 NK cells exhibit greater degranulation. (A) NK cells
were cultured for 6 days with IL-2 and then tested for degranulation
against K562 target cells over 1 min, 1 h or 2 h. NK cells were gated by
HLA-DR expression, representative of six donors. (B) Degranulation
(CD107a1) was compared between HLA-DR and HLA-DR1 NK cells for
six donors, po0.05, tested by Wilcoxon matched pairs, median7
interquartile range. (C) NK cells from the same donors were incubated
with K562 target cells or stimulated with PMA/ionomycin for 5 h, then
analysed by flow cytometry for intracellular IFN-g. Percentage of IFN-g1
NK cells was compared between HLA-DR and HLA-DR1 NK cells,
tested by Wilcoxon matched pairs.
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concept of NK cells as regulators of an adaptive immune response
[32–34]. Together, these data are consistent with HLA-DR-
expressing NK cells playing a role in establishing the immune
response to BCG and we next set out to test this specifically.
HLA-DR-expressing NK cells aid the immune response
to BCG
Understanding the heterogeneity in human responses to patho-
gens is an important new frontier in contemporary immunology.
The specific designation of low and high IFN-g secretion
responses to malaria has been noted previously [34–36]. Here,
we classified donors as ‘‘low’’ responders to BCG if fewer than
6.5% of their NK cells stained positively for IFN-g and as ‘‘high’’
responders if more than 6.5% did so. We then analysed the
frequency of HLA-DR-expressing NK cells in PBMCs from low
(n59) or high (n57) responders to BCG. In freshly isolated NK
cells, high responders had 2.5-fold more HLA-DR-expressing NK
cells (p50.03, Fig. 5D). Thus, the size of the circulating
population of HLA-DR-expressing NK cells can be associated
with IFN-g secretion by NK cells in PBMCs stimulated with BCG.
To test the role of HLA-DR-expressing NK cells directly, we
repeated the BCG stimulations using PBMCs enriched with
autologous HLA-DR-expressing NK cells, obtained by magnetic
separation of the HLA-DR1 fraction of NK cells previously isola-
ted from PBMCs. Importantly, a relatively modest enrichment of
HLA-DR-expressing NK cells (median 44% increase, Fig. 5E
and F) was sufficient to enhance the NK cell IFN-g response by
over three-fold (median 3.3-fold increase, p5 0.008, Fig. 5G
and H). Thus, although the HLA-DR-expressing NK cells are a
small population in ex vivo PBMCs, they can significantly influ-
ence immune responses to BCG.
Discussion
The expression of HLA-DR on NK cells has previously been used
as a marker of cellular activation [10–17]. However, the
expression of HLA-DR was only observed on a proportion of NK
cells and took 3 days or more, which is not consistent with
HLA-DR being a simple marker of NK cell activation. This is in
contrast with other activation markers, such as CD69, which is
expressed on the vast majority of activated cells within 18 h of
IL-2 stimulation [23]. By following proliferation of human NK
cells (via dilution of CFSE), we demonstrate here that HLA-DR is
expressed on cells that proliferate in response to IL-2 or IL-15. In
addition, NK cells derived by clonal expansion of a single seed cell
were relatively homogeneous in their expression of HLA-DR.
These data suggest that expression of HLA-DR after culture of NK
cells in IL-2 is due to the expansion of a distinct subset of HLA-
DR-expressing NK cells. This model was confirmed by our finding
that NK cells sorted for HLA-DR expression proliferate far more
readily than those lacking HLA-DR expression ex vivo.
There is considerable precedence for plasticity in NK cell
subsets. For example, IL-21 and IL-2 together can induce
upregulation of CD56 on CD56dim NK cells [9]. In addition, after
7 days co-incubation with LPS-matured DCs, most NK cells have
been shown to express HLA-DR [19]. Our data do not exclude
the possibility of de novo expression of HLA-DR on NK cells,
particularly following other stimuli. Nevertheless, an important
implication is that the large volume of human NK cell research
that uses peripheral blood NK cells expanded in IL-2 involves
preferential expansion of a small subset of NK cells. Functional
analyses of such cells will be skewed towards the responses of the
HLA-DR-expressing NK cells rather than the bulk of circulating
NK cells.
These data also suggest that the accumulation of HLA-DR-
expressing NK cells at sites of inflammation [10, 19] may reflect
Figure 4. HLA-DR1 NK cells express a functional chemokine receptor
CXCR3. (A) NK cells from one donor ex vivo (left) and after
6 days culture with IL-2 (right) were analysed by flow cytometry for
expression of HLA-DR and CXCR3. (B) NK cells cultured with IL-2 for 6
days were analysed by flow cytometry for expression of HLA-DR and
CXCR3. The intensity (geomean) of CXCR3 expression was compared
between HLA-DR and HLA-DR1 populations. (C) Comparison of
CXCR3 expression (right) on non-proliferating (grey shaded) and
proliferating (black) NK cells as gated in the CFSE histogram (left).
(D) NK cells from three donors were cultured with IL-2 for 6 days, then
assessed for their chemotactic response to the CXCR3 ligand I-TAC in a
transmigration chemotaxis assay. The percentage of NK cells that
responded was calculated by haemocytometer — counting the cells in
the lower chamber. (E) The transmigrated cells were also analysed by
flow cytometry for expression of HLA-DR, plotted as the enrichment of
HLA-DR1 NK cells in the transmigrating cells, relative to the buffer
control, and (F) expression of CXCR3 on transmigrated NK cells. (D–F)
n5 3, median7range.
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CXCR3-mediated recruitment or in situ expansion of the HLA-DR-
expressing NK cells, rather than NK activation per se. Moreover,
the human HLA-DR-expressing NK cell subset identified here could
be analogous to the population of murine cells initially designated
IFN-producing killer DCs [37, 38], which are now more properly
thought of as a subset of activated NK cells [39, 40].
An important goal is to address the functional importance of
HLA-DR-expressing NK cells. It has been shown previously that
NK cells expressing HLA-DR can present antigen to trigger T-cell
proliferation and IL-2 production [18–19]. The accumulation of
HLA-DR-expressing NK cells at sites of inflammation [10, 19] and
correlations between their numbers and the magnitude of
immunopathology (for example in IgA nephropathy [20])
suggests that they may contribute to inflammation and immuno-
pathology, either by antigen presentation or an alternative
mechanism. In support of this, we have observed that the
HLA-DR-expressing NK cells exhibit a significantly stronger
cytolytic activity, compared with other NK cells. This corresponds
with the described ‘‘presentation after killing’’ mechanism of
antigen acquisition via internalisation of engaged NK cell acti-
vating receptors and subsequent trafficking to class II MHC
protein-loading compartments [41].
To fulfil a role as APCs, HLA-DR-expressing NK cells would
need to encounter antigen-specific T cells. For conventional APCs
this most frequently occurs in secondary lymphoid organs, such
as lymph nodes. Importantly, HLA-DR1 NK cells have been
reported to account for 50% of NK cells in lymph nodes [22]
consistent with our observation here of high levels of expression
of the lymph node-homing receptor CXCR3 on them. Thus, as in
mice [8, 27], CXCR3 may play an important role in recruiting
HLA-DR-expressing NK cells to secondary lymphoid organs.
One important area of contemporary immunology is to
understand and parameterise heterogeneity amongst human
immune systems and responses [42]. One recent example is the
considerable heterogeneity amongst naı¨ve donors in NK cell
IFN-g secretion in response to malaria-infected erythrocytes [35].
This NK cell secretion of IFN-g can be inhibited by blocking MHC
class II proteins or IL-2, and by depleting antigen-specific CD41
T cells, thus positioning the IFN-g-secreting NK cells as important
regulators during an antigen-specific recall response [32–34].
Here, we found a similar dependency on MHC class II proteins,
CD41 T cells and IL-2, consistent with the NK cell secretion of
IFN-g in response to BCG stimulation acting as an important
regulator mechanism during the adaptive immune response.
Moreover, by specifically enlarging the HLA-DR-expressing
compartment, NK cell secretion of IFN-g in response to BCG could
be enhanced. It can be speculated that this is due to antigen
presentation by HLA-DR-expressing NK cells, which could
Figure 5. Enrichment of HLA-DR1 NK cells enhances the IFN-g response to BCG. (A) PBMCs from ten donors were cultured with BCG for up to
6 days and the percentage of CD561CD3 NK cells staining positive for HLA-DR was measured by flow cytometry, median7interquartile range,
po0.01 tested by Wilcoxon matched pairs. (B) PBMCs from 78 donors were cultured with BCG for 24 h then analysed by flow cytometry for
intracellular IFN-g in NK cells, dotted line represents the median (6.5%). (C) PBMCs from ten donors were cultured with BCG for 24 h with blocking
antibodies to MHC molecules or to IL-2 or with isotype matched controls. The percentage of IFN-g1 NK cells was determined by flow cytometry,
po0.01 tested by Wilcoxon matched pairs. (D) PBMCs from 16 donors (seven high and nine low responders) were analysed by flow cytometry for
the percentage of HLA-DR-expressing NK cells, median7interquartile range, po0.05 tested by Mann Whitney one-tailed test. (E) PBMCs were
enriched for HLA-DR1 NK cells and confirmed by flow cytometry; gates indicate percentage of HLA-DR1 NK cells. (F) HLA-DR-expressing NK cell
enrichment for five donors, po0.05 tested by Mann Whitney. (G) PBMCs (top) or HLA-DR1 NK cell-enriched PBMCs (bottom) were cultured for 24 h
with growth medium control (GM, left) or with BCG (right) then analysed by flow cytometry for intracellular IFN-g in CD561CD3 NK cells; gates
indicate percentage of IFN-g1 NK cells. (H) Data for five donors, median7interquartile range, po0.01 tested by Wilcoxon matched pairs.
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perhaps be mediated by uptake via the NK cell activating receptor
NKp44, which can bind components of the mycobacterial cell
wall [43], but this remains to be tested specifically.
It is intriguing that there was significant heterogeneity
amongst donors in the NK cell secretion of IFN-g in response to
BCG. This heterogeneity was associated with the size of the
circulating HLA-DR-expressing NK cell population, which
suggests that heterogeneity in human immune responses to BCG,
at least in vitro, can be linked to the size of the HLA-DR-
expressing NK cell compartment in peripheral blood. This gives a
novel suggestion to why individuals consistently respond differ-
ently to BCG and other pathogens, and could have important
implications in understanding differences between donors in the
efficacy of the BCG vaccine. Taken together, these data suggest a
specific and important immunological function for the subset of
human NK cells that express HLA-DR.
Materials and methods
Cells
Healthy adult donors gave fully informed consent for their blood
to be used in this study, which was approved by the London
School of Hygiene and Tropical Medicine and by the Riverside
NHS research ethics committees as appropriate. Venous blood
was collected into sodium heparin (10 IU/mL blood; CP
Pharmaceuticals), and PBMCs were isolated by Histopaque
1077 (Sigma-Aldrich, St. Louis, MO) density gradient centrifuga-
tion as described previously [44]. NK cells were isolated from
PBMCs by negative selection using magnetic activated cell sorting
(LS columns, Miltenyi Biotech).
Where specified, NK cells were depleted from PBMCs using
CD56 microbeads, or HLA-DR1 NK cells were separated from NK
cells using HLA-DR microbeads, followed by magnetic separation
(Miltenyi Biotech). Isolations and depletions were confirmed by
flow cytometry for expression of CD3, CD56 and HLA-DR. NK cells
were cultured in X-vivo-10 media (Lonza) supplemented with 10%
heat-inactivated FCS with recombinant (r)IL-2 (200 U/mL,
Roche), rIL-12 or rIL-15 (both 10 ng/mL, R&D systems). Freshly
isolated human NK cells were sorted into CD561/HLA-DR1 and
CD561/HLA-DR populations by flow cytometric cell sorting
(BD FACS Aria II). The percentage of HLA-DR-expressing NK cells
in a polyclonal population after 6 days culture with IL-2 that
derived from the small initial population of HLA-DR-expressing
NK cells ex vivo was calculated by factoring the percentage of
HLA-DR1 NK cells (%DR1) in each sorted population (subscript
DR or DR1) by the relative population size (rel.pop.), according to
the following equation,
ð%DR1DR1=rel:pop:DR1Þ  100
ð%DR1DR1=rel:pop:DR1Þ1ð%DR
1
DR=rel:pop:DRÞ
 
NK cell clones were generated from isolated NK cells as described
previously [44]. Briefly, freshly isolated NK cells were seeded by
limiting dilution in 96-well round-bottom plates and cultured for
4 wk. K562 cells were cultured in RPMI supplemented with
10% heat-inactivated FCS, 1% penicillin/streptomycin and 1%
L-glutamine (both Gibco).
Flow cytometry
Samples were labelled with directly conjugated mouse mAbs
in 2% BSA/0.01% sodium azide/PBS for 30 m on ice. The
following antibodies were purchased from BD Biosciences: anti-
CD3 FITC (clone UCHT1, IgG1), anti-CD3 PE/APC (clone
HIT3a, IgG2a), anti-CD56 FITC/PE/APC (clone B159, IgG1),
anti-HLA-DR FITC/PerCP (clone L243, IgG2a; confirmed with
clone TU¨36, IgG1), anti-IFN-g APC (clone B27, IgG1). In
addition, the following antibodies were used: anti-CD69
APC (Biolegend, clone FN50, IgG1), anti-CXCR3 APC (R&D
Systems, clone 49801, IgG1). Samples were acquired on a
FACSCalibur (BD Biosciences) and data analysed using
FlowJo software (TreeStar, OR). Propidium iodide (Invitrogen)
was used for live/dead cell discrimination. Freshly isolated
human NK cells were labelled with 1mM CFSE for 15 m at 371C
in RPMI, then washed three times before stimulation in culture
media. CFSE dilution in proliferating cells was analysed by flow
cytometry.
Cell stimulations
Purified PBMCs were plated at 2 106 cells/mL in 96-well
round-bottom plates and stimulated with BCG for 24 h at a MOI
(BCG:PBMC) of 10:1, the optimal ratio determined by titration
(Supporting Information Fig. S7). Samples were analysed for
expression of CD3, CD56, HLA-DR and IFN-g by flow cytometry.
Functional assays
To assay for NK degranulation, NK cells were co-incubated with
K562 target cells for 1 min, 1 h or 2 h with PE-conjugated anti-
CD107a mAbs included in the media (clone H4A3, IgG1, BD
Biosciences). Samples were harvested, stained for surface
markers, fixed with 2% PFA/PBS and analysed by flow cytometry.
To determine secretion of IFN-g, NK cells were incubated with
K562 target cells or PMA (50 ng/mL)/ionomycin (1mg/mL, both
Sigma Aldrich) for 5 h. Aliquots of 10 mg/mL Brefeldin A (Sigma
Aldrich) were added to the wells 4 h before samples were
harvested. Samples were stained for surface markers, then
fixed and permeabilised (CytoFix and PermWash buffer, BD
Biosciences), before staining for intracellular IFN-g and analysed
by flow cytometry. Chemotaxis assays were performed as
previously described [45], using ChemoTX plates with a 5mm
pore size, (Neuroprobe, Gaithersburg, MD) and the chemokine
I-TAC (PeproTech, EC). For NK cell migration, enumeration was
carried out using a haemocytometer, with individual results
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expressed as a percentage of the total cells applied to the filter.
The phenotype of the responding NK cells was analysed by flow
cytometry. Enrichment of the HLA-DR1 NK cells was calculated
by subtracting the percentage of HLA-DR1 NK cells that migrated
in the buffer-only sample, from that at each chemokine
concentration, and expressed as a percentage of the buffer-only
control for comparison. CXCR3 internalisation was measured by
analysing surface expression of CXCR3 by flow cytometry on the
migrated NK cells. The intensity of expression (calculated as
geomean of fluorescence) was compared with that in the buffer-
only control sample.
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